← ニュース一覧へ戻る
Lilly Pumps $3B Into China to Boost Supply of Weight-Loss Pill
2026-03-11 21:24
基本情報
| 調達額 | $3.0B |
|---|---|
| ラウンド | - |
| 投資家 | - |
| カテゴリ | バイオ |
| 展開スコア | 0 |
| 出典 | https://www.biospace.com/business/lilly-pumps-3b-into-china-to-boost-supply-of-weight-loss-pill |
要約
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.